USP Monograph Could Substitute For ANDA Chemistry Review, Williams Says
Chemistry reviews for ANDAs conforming to a USP monograph could be eliminated, U.S. Pharmacopoeia CEO-designate Roger Williams, MD, told the National Association of Pharmaceutical Manufacturers annual meeting.
You may also be interested in...
FDA's proposed rule "Supplements and Other Changes to an Approved Application" and its accompanying guidance should be abandoned, the Pharmaceutical Research & Manufacturers of America asserted in Aug. 27 comments to the agency.
FDA is proposing to grant waivers of in vivo bioequivalence tests for certain immediate-release solid oral dosage form drugs that meet the characteristics of being highly permeable, soluble and having rapid dissolution.
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011